Tg Therapeutics, Inc.
TGTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$54.17
KIRA · Stoqly’s AI analyst, in plain words
- Tg Therapeutics, Inc. had $616M of revenue in fiscal 2025, up 87.3% on the year before. Over five years, revenue changed +426.7% a year on average.
- Its operating margin was 20.0%, up 7.3 pts: of every 100 in sales, about 20 is left after running the business.
- Tg Therapeutics, Inc. made $447M of net profit in fiscal 2025.
- Free cash flow was −$25.0M in fiscal 2025, −4.1% of revenue.
- Tg Therapeutics, Inc. owes $104M more than it holds in cash, about 0.8 years of operating profit.
Market cap
$8.5B
P/E
19.8x
Revenue
$616M
Net income
$447M
Free cash flow
−$25.0M
Operating margin
20.0%
Tg Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+87.3%
Yes. Sales grew 87.3% last year.
Does it make a profit?
72.6%
Yes. It keeps 72.6% of every sale as profit.
Does profit turn into cash?
−4.1%
No. It spent more cash than it brought in.
Is debt under control?
0.8x
Yes. It could repay its debt with 0.8 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
19.8x
One share costs 19.8 times its yearly profit per share.
What Tg Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- TG THERAPEUTICS, INC.
- CIK
- 0001001316
Tg Therapeutics, Inc. · TGTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $6.7M | $2.8M | $234M | $329M | $616M |
| Revenue growth | 4,300.7% | −58.4% | 8,290.0% | 40.8% | 87.3% |
| Gross margin | 88.2% | 90.5% | 94.0% | 88.3% | 83.7% |
| Operating margin | −5,154.3% | −7,839.0% | 8.8% | 12.7% | 20.0% |
| Net income | −$348M | −$224M | $12.7M | $23.4M | $447M |
| Net margin | −5,204.1% | −8,036.3% | 5.4% | 7.1% | 72.6% |
| Diluted EPS | −$2.63 | −$1.65 | $0.09 | $0.15 | $2.77 |
| Cash | |||||
| Cash from operations | −$296M | −$176M | −$31.4M | −$40.5M | −$24.8M |
| Capital expenditure | $0.4M | $0.0M | $0.0M | $0.0M | $0.2M |
| Free cash flow | −$296M | −$176M | −$31.4M | −$40.6M | −$25.0M |
| FCF margin | −4,425.7% | −6,326.2% | −13.4% | −12.3% | −4.1% |
| Share count change | 14.6% | 2.4% | 9.7% | 8.0% | 0.7% |
| Debt and strength | |||||
| Cash and short-term investments | $315M | $162M | $218M | $311M | $142M |
| Debt incl. finance leases | $67.8M | $71.1M | $100M | $244M | $246M |
| Shareholders' equity | $237M | $58.6M | $161M | $222M | $648M |
| Net debt / EBITDA | — | — | −5.6x | −1.6x | 0.8x |
| Current ratio | 5.1x | 3.2x | 5.9x | 6.2x | 4.1x |
| Interest coverage | −61.2x | −21.4x | 1.6x | 1.7x | 4.6x |
| Returns and quality | |||||
| Return on capital | — | — | 46.1% | 24.6% | 16.4% |
| Return on equity | −92.0% | −151.4% | 11.6% | 12.2% | 102.8% |
| Return on tangible equity | −147.3% | −387.3% | 7.9% | 10.5% | 69.0% |
| Piotroski F-score | 2 | 2 | 6 | 3 | 4 |
| Altman Z'' | −11.2 | −28.9 | −8.7 | −2.1 | 2.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tg Therapeutics, Inc. · TGTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $54.17 a share, the company is worth $8.5B: 19.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001001316). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.